Ataluren for treating Duchenne Muscular Dystrophy with a nonsense mutation in the dystrophin gene, Policy Position Statement (PP118), July 2023.pdf (PDF, 217Kb)
Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis Type 2 (now known as NF2-related vestibular schwannomatosis) (all ages), Commissioning Policy (CP254), August 2023.pdf (PDF, 440Kb)
Selective Dorsal Rhizotomy (SDR) for the treatment of spasticity in cerebral palsy in children aged 3-9 years, Policy Position Statement (PP245), March 2024.pdf (PDF, 975Kb)
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over, Policy Position Statement (PP267), September 2023.pdf (PDF, 228Kb)
Transcranial magnetic resonance guided focused ultrasound (TcMRgFUS) thalamotomy for treatment of medication-refractory essential tremor for people aged 18 and over, (PP258), August 2023 (PDF, 298Kb)